Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-arm open-label gene therapy study of BBM-H803 injection in hemophilia A
CTR20233400Phase 3Active
- Sponsor
- Zelgen
- Start
- Jan 2024
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of BBM-002 in hemophilia A, sponsored by Zelgen. Primary endpoints: DLT incidence in Phase I/II, Adverse event (AE) and serious adverse event (SAE) incidence in Phase I/II and 2 more. Started Jan 2024; status: active.
02
Drugs
BBM-002
03
Conditions
hemophilia A
Beyond the preview
Go deeper on CTR20233400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233400.